Chronic inflammation is involved in tumor development, tumor colorectal cancer progression, progression and metastasis and, also, in resistance to therapy.
As it is already acknowledged inflammatory bowel diseases IBD such as ulcerative colitis and Crohn disease are closely linked to an increased risk of colorectal cancer as high as 10 fold. Various inflammatory cytokines have been studied as they facilitate the tumor development.
Among those the most relevant are: C reactive protein, interleukin 6 and tumor necrosis factor alpha. The majority of published studies points toward a positive link between the increased serum level of those inflammatory molecules and the risk of colorectal cancer.
Future studies are needed to address the issue of novel oncological therapy that interfere with inflammatory mechanism of colorectal cancer. However, users may print, download, or email articles for individual use.
This abstract may be abridged. No warranty is given about the accuracy of the copy.
Users should refer to the original published version of the material for the full abstract. Important User Information: Remote access to EBSCO's databases is permitted to patrons of subscribing institutions accessing from remote locations for personal, non-commercial use.
However, remote access to EBSCO's databases from non-subscribing institutions is not allowed if the purpose of the use colorectal cancer progression for commercial gain through cost reduction or avoidance for a non-subscribing institution.